Results 171 to 180 of about 34,942 (245)

Pharmacogenomics and genetic ancestry: an opportunity to transform clinical practice in Colombia. [PDF]

Front Pharmacol
Acosta-Monterrosa AA, Montoya-Quintero KF, Barceló-Martinez E, Galván-Barrios J.   +3 more
europepmc   +1 more source

Benchmark of Open‐Access Star‐Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 520-530, August 2026.
Genetic polymorphisms are common in pharmacogenes, with sometimes important implications for drug metabolism. Assessing the correct enzyme phenotype from genetic data is thus a crucial step into the development of personalized medicine. Many bioinformatics star‐allele callers have been developed for this purpose of identifying the correct star alleles ...
Marc B. Gros‐La‐Faige, Emmanuelle Génin, Anthony F. Herzig   +2 more
wiley   +1 more source

The critical need to implement pharmacogenomics in public health services: Mexico in the global picture. [PDF]

Front Public Health
Perezcano C.
europepmc   +1 more source

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang, D. Q. Cai, Zhen Zhao, Zhixiang Jian, Mude Shi, Yajin Chen, Jueming Chen, Chunhua Qu, Diankui Cai   +8 more
wiley   +1 more source

Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals' perceptions, knowledge, and educational needs. [PDF]

Pharmacogenomics J
Panconesi D, Murtough S, Cotic M, Khani NS, Varney L, Richards-Brown M, Abidoph R, Mills D, Richards-Belle A, Molai J, Fenwick J, Curwen J, Allin M, Berry A, Barczyk M, Bonaccorso S, Griffiths R, Bernini M, Kumar A, Senthilkumar S, Dawda Y, Shokkar R, Murdoch R, Crane J, Rahimi Y, Howard M, Welfare-Wilson A, Secchi A, Thomas C, Pastor B, Sharma P, Pius G, Nazir R, Mir A, Cheshire J, Bostock R, Gibbon S, Singh P, Shah C, Richards S, Cheung SB, Rowe-Leete L, Jibero A, Cox R, Van Driel P, Bramon E.   +45 more
europepmc   +1 more source

Investigation of the Prevalence of the HLA‐B*15:02 Allele in the Asian Populations: A Comprehensive Analysis Through Using AFND

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims The HLA‐B*15:02 allele is related to a high risk of severe cutaneous adverse drug reactions (SCARs) in patients taking certain antiepileptic drugs. However, its prevalence in the Asian population and the number of drugs linked to SCARs due to the carriage of this variant are relatively underexplored.
Mohitosh Biswas, Murshadul Alam Murad, Maliheh Ershadian, Chonlaphat Sukasem   +3 more
wiley   +1 more source

A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics. [PDF]

Pharmacogenomics J
Sundermann AC, Marryshow Batson SE, Jasper EA, Jones SH, Fountain DF, Liu M, Sunthankar SD, Velez Edwards DR.   +7 more
europepmc   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source

Consumer Experiences and Perceptions of Genetic Counseling in Provider‐Mediated Genetic Testing

Journal of Genetic Counseling, Volume 35, Issue 4, August 2026.
ABSTRACT Provider‐mediated genetic testing (PM‐GT) is a hybrid model in which consumers initiate testing online, but a physician, typically from a third‐party network, is required to order the test. While genetic counseling is a critical component of result interpretation and medical decision‐making, its integration into PM‐GT remains limited.
Katherine A. Lauro, Bob Wong, Jason Iuliano, Margaret Peo, Jacqueline Park, Karin M. Dent, Angela R. Bradbury, Madison K. Kilbride   +7 more
wiley   +1 more source

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocol. [PDF]

HRB Open Res
Stollarova N, Ryan C, Sheaf G, Keating D, O'Donoghue B, Cadogan C.   +5 more
europepmc   +1 more source